Safe Disposal and Destruction: Articles 48-50 and Disposal Approval
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Articles 48-50 write the safe disposal of medical products into a matter requiring approval. Working together with Article 39, which prohibits counterfeit, defective and expired products, the UAE applies dual-track management of circulation prohibition plus approved disposal to expired, recalled and non-conforming devices. Our judgment is that the link where device companies most often go wrong is treating recalled and expired products as ordinary stock and destroying them on their own initiative. The reason is that disposal approval is a statutory precondition; disposal without approval is itself a violation, and it breaks the closure evidence chain of the recall, since the company cannot prove that the products lawfully exited the market and will have to re-explain their whereabouts in later EDE checks.
- Articles 48-50 make safe disposal of medical products an activity requiring approval.
- Article 39 prohibits counterfeit, defective and expired products; Articles 48-50 are the only lawful way out for them.
- Disposal without approval is itself a violation and breaks the closure evidence chain of a recall.
- The fixed sequence is: segregate first, then apply for approval, then execute; destruction first and paperwork later is prohibited.
2. Legal basis
The three disposal articles, the prohibition they hang from, and the import permit provision implicated when disposal goes wrong are set out below.
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 48 | Articles 48-50 govern the approval, conditions and validity period of safe disposal of medical products |
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 49 | Articles 48-50 govern the approval, conditions and validity period of safe disposal |
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 50 | Articles 48-50 govern the approval, conditions and validity period of safe disposal |
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 39 | Counterfeit, defective and expired products are prohibited |
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 33 | Import and export permits and their revocation; a connected consequence of improper disposal |
3. Expert insights
Insight 1: Disposal is an approval matter, not an internal operation of the company. Our professional judgment is that destroying products on one’s own initiative without approval means the compliance loop has not been closed. The reason is that Articles 48-50 design disposal as an act requiring approval, and a company’s destruction acquires legality only when it falls after the approval. On the trade-off, the correct sequence is to quarantine and hold in the warehouse first, execute only after the disposal approval has been obtained, and archive the approval documents together with the execution records, rather than destroying first and completing the paperwork afterwards.
Insight 2: The junction between Article 39 and Articles 48-50 lies in defective and expired products. The judgment is that defective and expired products may neither circulate nor be disposed of on the company’s own initiative; the approval path is the only route. The reason is that Article 39 is a prohibitive provision and Articles 48-50 are the sole outlet, and together the two close off every other form of handling. On the trade-off, the warehouse standard operating procedures should segregate defective goods, expired goods and recalled goods individually, physically separated from conforming stock and kept on separate accounts, so that they are not mistakenly shipped as conforming goods after being mixed together.
Insight 3: Disposal records are the last piece of the recall closure. The judgment is that the evidence of the effectiveness of a field safety corrective action (FSCA) depends on the disposal records; without them, the recall is not complete at the regulatory level. The reason is that the rights holder obligations under Article 21 connect directly to the disposal outcome. On the trade-off, the three documents of disposal approval, disposal execution and proof of disposal should be archived together, forming a complete chain from taking products in to destruction; missing any one of them may attract a request for supplementary explanation in later checks.
4. Practical recommendations
- In the warehouse standard operating procedures, segregate expired goods, defective goods and recalled goods individually, physically separated from conforming stock and kept on separate accounts.
- Fix the disposal process as segregate first, then apply for approval, then execute; destroying first and completing the paperwork afterwards is prohibited.
- Archive the 3 documents of disposal approval, disposal execution and proof of disposal together, forming a complete chain.
- Agree with the responsible entity on deadlines for consolidating and handing over recalled products, so that products do not linger in the distribution stage.
- The disposal contractor must hold the relevant qualifications, and the engagement documents must state the disposal method and the obligation to issue proof documents.
- Link the disposal ledger with the vigilance ledger and the PSUR ledger, so that the status of the same batch is consistent across the three sets of records.
5. Verification checklist
- □ Expired goods, defective goods and recalled goods are physically segregated in the warehouse and kept on separate accounts
- □ The disposal process is segregate first, then apply for approval, then execute, with no cases of destruction first
- □ The three documents of disposal approval, disposal execution and proof of disposal are archived together
- □ Deadlines for consolidating and handing over recalled products have been agreed with the responsible entity
- □ The contractor’s qualifications and the obligation to issue proof documents are written into the engagement documents
- □ The batch status in the disposal ledger is consistent with the vigilance ledger and the PSUR ledger
- □ How the circulation prohibition of Article 39 is executed in warehouse operations has been verified
Further reading: Article No. 43, Field Safety Corrective Actions (FSCA) and Recalls: Withdrawal Procedures and Responsibility Allocation; Article No. 48, Penalties and Appeals: Articles 160, 162 and 168 and the AED 1,000-1,000,000 Range; Article No. 38, The Two-Stage Import Permit: Pre-Permit, Arrival Clearance and the 2-Month Validity.
Regulatory information verified as of October 29, 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team manages adverse event reporting and recall coordination with MOHAP, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us